Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor

A receptor binding, anti-idiotypic technology, applied in immunoglobulin, anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc.

Inactive Publication Date: 2006-08-09
NOVARTIS AG
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A possible disadvantage of this type of BSW17 mimotope peptide vaccine is that the chemically synthesized peptide needs to be coupled to a carrier protein to enhance the immunogenicity of the peptide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
  • Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
  • Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Example 1: Construction of phage display library

[0134] a) Source of lymphocytes

[0135] Mononuclear cells (NMC) were prepared from peripheral blood of two adult male donors. The first male adult atopic donor with clinical signs of allergy was boosted with an intramuscular injection of 0.5 ml of tetanus toxoid adsorbed on aluminum adjuvant (Te Anatoxal Bern, Swiss Serum and Vaccine Institute, Bern, Switzerland). Seven days later MNCs were isolated by gradient centrifugation using Ficoll (Pharmacia, Lymphoprep, Milwaukee, WI, USA). Then with 10 3 U / ml interleukin 2 (Sigma, St-Louis, MO, USA), 50 μg / ml Pansorbin cells (Staphylococcus aureus Cowan strain 1, Calbiochem, La Jolla, California, USA) and 1:1000 dilution with RPMI-1640 medium Tetanus toxoid was cultured in RPMI-1640 (Seromed, Basel, Switzerland) medium for 3 days. Total RNA was prepared from these cells using the phenol-chloroform guanidine isothiocyanate procedure (Chomczynsi, P. and Sacci, N., Aha...

Embodiment 2

[0164] Example 2: Screening of recombinant BSW17-specific antibody fragments (BSW17- mock antibody)

[0165] BSW17-specific phage selection was performed by four rounds of panning. In each round, two pre-adsorptions were performed with anti-IgE-mAb Le27 prior to adsorption of anti-IgE mAb BSW17. Pre-adsorption was performed as follows: two immunotubes (Maxisorp, Nunc) were coated with 4ml Le27 (20 μg / ml) overnight at 4°C and then blocked with 4ml PBS / 2% skim milk for 2 hours at 37°C. The first tube contains 2 x 10 in 4ml 12 The cfu blocking solution of each phage library (BS, LD2 and CT) was incubated with shaking at room temperature for 30 minutes. The phages were then transferred to a second tube and the procedure repeated. After the second pre-absorption, non-Le27-specific phages were added to tubes coated with 4 ml BSW17 (20 μg / ml) and blocked with PBS / 2% skim milk as above. After incubation at room temperature for 2 hours with shaking. The tubes were washed succe...

Embodiment 3

[0169] Example 3: Nucleotide sequence of recombinant BSW17-mimetic antibody

[0170] Plasmid DNA was prepared from selected phage clones using the Nucleotrap kit (Machery-Nagel, Duren, Germany). And use the PRISM Ready Reactin DyeDeoxy Terminator CycleSequencing Kit (Applied Biosystems, Germany) kit to perform nucleic acid sequence determination on the ABI 373A sequencing system.

[0171] Primers used for heavy chain sequencing were:

[0172] CHγ1(5′-CGCTGTGCCCCCAGAGGT-3′)( Seq.id.no.20 )and

[0173] pCH(5′-GGCCGCAAATTCTATTTCAAGG-3′)( Seq.id.no.21 ).

[0174] To obtain the light chain sequence, the following primers were used:

[0175] Cλ(5′-GAGACACACCAGTGTGGC-3′)( Seq.id.no.22 ),

[0176] CK(5′-CACAACAGAGGCAGTTCC-3′)( Seq.id.no.23 )and

[0177] pCL(5′-CTAAACTAGCTAGTCGCC-3′)( Seq.id.no,24 ).

[0178] Primers were synthesized by Microsynth (Balgach, Switzerland). From the DNA sequences of the selected different phage clones, two different amino acid sequences...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Antibodies and antibody fragments which are anti-idiotypic to an antibody that interferes with the binding of the C epsilon 3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti-idiotypic to BSW17 (BSW17-mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE-mediated diseases.

Description

technical field [0001] The present invention relates to anti-idiotypic antibodies. The present invention relates to the inhibition of the interaction of cell-bound IgE binding to allergens to induce activation of mast cells and basophils, resulting in the release of histamine and other mediators and cells involved in the regulation of allergic and inflammatory responses de novo synthesis of factors. The present invention relates to an anti-idiotypic antibody or antibody fragment that interferes with the binding of Cε3 region of IgE to IgE high-affinity receptor. Background technique [0002] Knowledge of the specific binding site on 1gE that interacts with its high-affinity receptor (FCεRI) provides the basis for generating antibodies that prevent this interaction by recognizing this binding epitope. Induction of such antibodies through vaccination has resulted in a new and generally applicable treatment for anaphylaxis. The present invention specifically describes the id...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/42C07K16/28A61K39/395A61P37/00A61P17/00C12N15/09A61K39/00A61K39/39A61P11/02A61P11/06A61P17/02A61P37/08C12P21/08
CPCC07K16/4241A61K2039/505C07K2317/21C07K2317/55A61P11/02A61P11/06A61P17/00A61P17/02A61P37/00A61P37/08C07K16/42
Inventor F·克里塞克B·斯塔德勒M·沃格尔
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com